Clinical features, treatment options and outcomes in primary cutaneous B‐cell lymphomas: a real‐world, multicenter, retrospective study
Background Primary cutaneous B‐cell lymphomas (PCBCLs) are rare cutaneous neoplasms with limited literature regarding treatment options and associated treatment outcomes. This study aimed to investigate and present real‐world treatment outcomes in patients with PCBCLs. Methods All patients with PCBC...
Saved in:
| Published in | International journal of dermatology Vol. 64; no. 5; pp. 882 - 889 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Blackwell Publishing Ltd
01.05.2025
John Wiley and Sons Inc |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0011-9059 1365-4632 1365-4632 |
| DOI | 10.1111/ijd.17564 |
Cover
| Abstract | Background
Primary cutaneous B‐cell lymphomas (PCBCLs) are rare cutaneous neoplasms with limited literature regarding treatment options and associated treatment outcomes. This study aimed to investigate and present real‐world treatment outcomes in patients with PCBCLs.
Methods
All patients with PCBCL who were treated in five major referral centers for cutaneous lymphoma in Greece over 10 years were retrospectively included with their baseline characteristics and treatment‐associated outcomes collected and analyzed.
Results
In total, 235 PCBCL patients, of whom 125 (53.2%) were females, were included. The median age at diagnosis was 60 years (IQR 47–72), and the median follow‐up duration was 3 years (IQR 1.3–6.4). The most common subtype was primary cutaneous marginal zone lymphoma (PCMZL) (52.3%), followed by primary cutaneous follicle center lymphoma (PCFCL) (40.9%), and primary cutaneous large B‐cell lymphoma, leg type (PCDLBCL, LT) with 16 (6.8%) cases. Complete responses (CRs) were observed in 77.3% after first‐line treatment. Both radiotherapy (RT) and surgical excision (SE) achieved superior outcomes, with 88.9% and 89% achieving CR, respectively. Relapses occurred in 22.6% of initial complete responders. The median time to the next treatment (TTNT) for the PCMZL and PCFCL was 349 days. RT and topical/intralesional steroids demonstrated longer TTNT compared to SE (445 and 359 vs. 154 days). For PCMZL and PCFCL, the 1‐year progression‐free survival (PFS) was 84.2% (75.7–89.9) and 85% (75.1–91.2), and the 5‐year PFS was 66.5% (55.2–75.5) and 58.8% (44.4–70.7), respectively.
Conclusions
PCBCLs have favorable outcomes. RT demonstrates significantly increased TTNT compared to SE, suggesting RT as the preferable option. After careful evaluation, “watch and wait” may be a reasonable option for asymptomatic patients.
Clinical features, treatment options and outcomes in PCBCL. |
|---|---|
| AbstractList | Background
Primary cutaneous B‐cell lymphomas (PCBCLs) are rare cutaneous neoplasms with limited literature regarding treatment options and associated treatment outcomes. This study aimed to investigate and present real‐world treatment outcomes in patients with PCBCLs.
Methods
All patients with PCBCL who were treated in five major referral centers for cutaneous lymphoma in Greece over 10 years were retrospectively included with their baseline characteristics and treatment‐associated outcomes collected and analyzed.
Results
In total, 235 PCBCL patients, of whom 125 (53.2%) were females, were included. The median age at diagnosis was 60 years (IQR 47–72), and the median follow‐up duration was 3 years (IQR 1.3–6.4). The most common subtype was primary cutaneous marginal zone lymphoma (PCMZL) (52.3%), followed by primary cutaneous follicle center lymphoma (PCFCL) (40.9%), and primary cutaneous large B‐cell lymphoma, leg type (PCDLBCL, LT) with 16 (6.8%) cases. Complete responses (CRs) were observed in 77.3% after first‐line treatment. Both radiotherapy (RT) and surgical excision (SE) achieved superior outcomes, with 88.9% and 89% achieving CR, respectively. Relapses occurred in 22.6% of initial complete responders. The median time to the next treatment (TTNT) for the PCMZL and PCFCL was 349 days. RT and topical/intralesional steroids demonstrated longer TTNT compared to SE (445 and 359 vs. 154 days). For PCMZL and PCFCL, the 1‐year progression‐free survival (PFS) was 84.2% (75.7–89.9) and 85% (75.1–91.2), and the 5‐year PFS was 66.5% (55.2–75.5) and 58.8% (44.4–70.7), respectively.
Conclusions
PCBCLs have favorable outcomes. RT demonstrates significantly increased TTNT compared to SE, suggesting RT as the preferable option. After careful evaluation, “watch and wait” may be a reasonable option for asymptomatic patients.
Clinical features, treatment options and outcomes in PCBCL. Primary cutaneous B-cell lymphomas (PCBCLs) are rare cutaneous neoplasms with limited literature regarding treatment options and associated treatment outcomes. This study aimed to investigate and present real-world treatment outcomes in patients with PCBCLs.BACKGROUNDPrimary cutaneous B-cell lymphomas (PCBCLs) are rare cutaneous neoplasms with limited literature regarding treatment options and associated treatment outcomes. This study aimed to investigate and present real-world treatment outcomes in patients with PCBCLs.All patients with PCBCL who were treated in five major referral centers for cutaneous lymphoma in Greece over 10 years were retrospectively included with their baseline characteristics and treatment-associated outcomes collected and analyzed.METHODSAll patients with PCBCL who were treated in five major referral centers for cutaneous lymphoma in Greece over 10 years were retrospectively included with their baseline characteristics and treatment-associated outcomes collected and analyzed.In total, 235 PCBCL patients, of whom 125 (53.2%) were females, were included. The median age at diagnosis was 60 years (IQR 47-72), and the median follow-up duration was 3 years (IQR 1.3-6.4). The most common subtype was primary cutaneous marginal zone lymphoma (PCMZL) (52.3%), followed by primary cutaneous follicle center lymphoma (PCFCL) (40.9%), and primary cutaneous large B-cell lymphoma, leg type (PCDLBCL, LT) with 16 (6.8%) cases. Complete responses (CRs) were observed in 77.3% after first-line treatment. Both radiotherapy (RT) and surgical excision (SE) achieved superior outcomes, with 88.9% and 89% achieving CR, respectively. Relapses occurred in 22.6% of initial complete responders. The median time to the next treatment (TTNT) for the PCMZL and PCFCL was 349 days. RT and topical/intralesional steroids demonstrated longer TTNT compared to SE (445 and 359 vs. 154 days). For PCMZL and PCFCL, the 1-year progression-free survival (PFS) was 84.2% (75.7-89.9) and 85% (75.1-91.2), and the 5-year PFS was 66.5% (55.2-75.5) and 58.8% (44.4-70.7), respectively.RESULTSIn total, 235 PCBCL patients, of whom 125 (53.2%) were females, were included. The median age at diagnosis was 60 years (IQR 47-72), and the median follow-up duration was 3 years (IQR 1.3-6.4). The most common subtype was primary cutaneous marginal zone lymphoma (PCMZL) (52.3%), followed by primary cutaneous follicle center lymphoma (PCFCL) (40.9%), and primary cutaneous large B-cell lymphoma, leg type (PCDLBCL, LT) with 16 (6.8%) cases. Complete responses (CRs) were observed in 77.3% after first-line treatment. Both radiotherapy (RT) and surgical excision (SE) achieved superior outcomes, with 88.9% and 89% achieving CR, respectively. Relapses occurred in 22.6% of initial complete responders. The median time to the next treatment (TTNT) for the PCMZL and PCFCL was 349 days. RT and topical/intralesional steroids demonstrated longer TTNT compared to SE (445 and 359 vs. 154 days). For PCMZL and PCFCL, the 1-year progression-free survival (PFS) was 84.2% (75.7-89.9) and 85% (75.1-91.2), and the 5-year PFS was 66.5% (55.2-75.5) and 58.8% (44.4-70.7), respectively.PCBCLs have favorable outcomes. RT demonstrates significantly increased TTNT compared to SE, suggesting RT as the preferable option. After careful evaluation, "watch and wait" may be a reasonable option for asymptomatic patients.CONCLUSIONSPCBCLs have favorable outcomes. RT demonstrates significantly increased TTNT compared to SE, suggesting RT as the preferable option. After careful evaluation, "watch and wait" may be a reasonable option for asymptomatic patients. Primary cutaneous B-cell lymphomas (PCBCLs) are rare cutaneous neoplasms with limited literature regarding treatment options and associated treatment outcomes. This study aimed to investigate and present real-world treatment outcomes in patients with PCBCLs. All patients with PCBCL who were treated in five major referral centers for cutaneous lymphoma in Greece over 10 years were retrospectively included with their baseline characteristics and treatment-associated outcomes collected and analyzed. In total, 235 PCBCL patients, of whom 125 (53.2%) were females, were included. The median age at diagnosis was 60 years (IQR 47-72), and the median follow-up duration was 3 years (IQR 1.3-6.4). The most common subtype was primary cutaneous marginal zone lymphoma (PCMZL) (52.3%), followed by primary cutaneous follicle center lymphoma (PCFCL) (40.9%), and primary cutaneous large B-cell lymphoma, leg type (PCDLBCL, LT) with 16 (6.8%) cases. Complete responses (CRs) were observed in 77.3% after first-line treatment. Both radiotherapy (RT) and surgical excision (SE) achieved superior outcomes, with 88.9% and 89% achieving CR, respectively. Relapses occurred in 22.6% of initial complete responders. The median time to the next treatment (TTNT) for the PCMZL and PCFCL was 349 days. RT and topical/intralesional steroids demonstrated longer TTNT compared to SE (445 and 359 vs. 154 days). For PCMZL and PCFCL, the 1-year progression-free survival (PFS) was 84.2% (75.7-89.9) and 85% (75.1-91.2), and the 5-year PFS was 66.5% (55.2-75.5) and 58.8% (44.4-70.7), respectively. PCBCLs have favorable outcomes. RT demonstrates significantly increased TTNT compared to SE, suggesting RT as the preferable option. After careful evaluation, "watch and wait" may be a reasonable option for asymptomatic patients. Clinical features, treatment options and outcomes in PCBCL. BackgroundPrimary cutaneous B‐cell lymphomas (PCBCLs) are rare cutaneous neoplasms with limited literature regarding treatment options and associated treatment outcomes. This study aimed to investigate and present real‐world treatment outcomes in patients with PCBCLs.MethodsAll patients with PCBCL who were treated in five major referral centers for cutaneous lymphoma in Greece over 10 years were retrospectively included with their baseline characteristics and treatment‐associated outcomes collected and analyzed.ResultsIn total, 235 PCBCL patients, of whom 125 (53.2%) were females, were included. The median age at diagnosis was 60 years (IQR 47–72), and the median follow‐up duration was 3 years (IQR 1.3–6.4). The most common subtype was primary cutaneous marginal zone lymphoma (PCMZL) (52.3%), followed by primary cutaneous follicle center lymphoma (PCFCL) (40.9%), and primary cutaneous large B‐cell lymphoma, leg type (PCDLBCL, LT) with 16 (6.8%) cases. Complete responses (CRs) were observed in 77.3% after first‐line treatment. Both radiotherapy (RT) and surgical excision (SE) achieved superior outcomes, with 88.9% and 89% achieving CR, respectively. Relapses occurred in 22.6% of initial complete responders. The median time to the next treatment (TTNT) for the PCMZL and PCFCL was 349 days. RT and topical/intralesional steroids demonstrated longer TTNT compared to SE (445 and 359 vs. 154 days). For PCMZL and PCFCL, the 1‐year progression‐free survival (PFS) was 84.2% (75.7–89.9) and 85% (75.1–91.2), and the 5‐year PFS was 66.5% (55.2–75.5) and 58.8% (44.4–70.7), respectively.ConclusionsPCBCLs have favorable outcomes. RT demonstrates significantly increased TTNT compared to SE, suggesting RT as the preferable option. After careful evaluation, “watch and wait” may be a reasonable option for asymptomatic patients. |
| Author | Nikolaou, Vasiliki Gerochristou, Maria Doxastaki, Aikaterini Patsatsi, Aikaterini Diavati, Stavrianna Kouloulias, Vassilis Papadavid, Evangelia Georgiou, Elisavet Papadopoulou, Vasiliki Tsamaldoupis, Athanasios Siakantaris, Marina Marinos, Leonidas Kaliampou, Stella Angelopoulos, Konstantinos Angelopoulou, Maria Machairas, Alexandros Kruger‐Krasagakis, Sabine Koumprentziotis, Ioannis‐Alexios Koumourtzis, Marios Vassilakopoulos, Theodoros Pappa, Vasiliki Kypraiou, Efrosini Koletsa, Triantafyllia Tsimpidakis, Antonios Stratigos, Alexander |
| AuthorAffiliation | 8 Department of Pathology Aristotle University School of Medicine Thessaloniki Greece 3 Cutaneous Lymphoma Clinic, Second Dermatology Department Aristotle University School of Medicine, Papageorgiou General Hospital Thessaloniki Greece 7 Second Department of Internal Medicine and Research Unit University General Hospital “Attikon” Athens Greece 2 Second Department of Dermatology, “Attikon” General Hospital National & Kapodistrian University of Athens, Medical School Athens Greece 5 Department of Dermatology University General Hospital of Heraklion Crete Greece 4 Department of Hematology and Bone Marrow Transplantation, Laikon General Hospital National & Kapodistrian University of Athens, Medical School Athens Greece 6 Hemopathology Department “Evangelismos” General Hospital Athens Greece 1 First Department of Dermatology, “Andreas Sygros” Hospital for Skin Diseases National & Kapodistrian University of Athens, Medical School Athens Greece |
| AuthorAffiliation_xml | – name: 8 Department of Pathology Aristotle University School of Medicine Thessaloniki Greece – name: 3 Cutaneous Lymphoma Clinic, Second Dermatology Department Aristotle University School of Medicine, Papageorgiou General Hospital Thessaloniki Greece – name: 7 Second Department of Internal Medicine and Research Unit University General Hospital “Attikon” Athens Greece – name: 6 Hemopathology Department “Evangelismos” General Hospital Athens Greece – name: 1 First Department of Dermatology, “Andreas Sygros” Hospital for Skin Diseases National & Kapodistrian University of Athens, Medical School Athens Greece – name: 5 Department of Dermatology University General Hospital of Heraklion Crete Greece – name: 2 Second Department of Dermatology, “Attikon” General Hospital National & Kapodistrian University of Athens, Medical School Athens Greece – name: 4 Department of Hematology and Bone Marrow Transplantation, Laikon General Hospital National & Kapodistrian University of Athens, Medical School Athens Greece |
| Author_xml | – sequence: 1 givenname: Vasiliki orcidid: 0000-0001-9340-9152 surname: Nikolaou fullname: Nikolaou, Vasiliki email: drviknik@yahoo.com organization: National & Kapodistrian University of Athens, Medical School – sequence: 2 givenname: Ioannis‐Alexios orcidid: 0000-0002-1156-7139 surname: Koumprentziotis fullname: Koumprentziotis, Ioannis‐Alexios organization: National & Kapodistrian University of Athens, Medical School – sequence: 3 givenname: Evangelia surname: Papadavid fullname: Papadavid, Evangelia organization: National & Kapodistrian University of Athens, Medical School – sequence: 4 givenname: Aikaterini surname: Patsatsi fullname: Patsatsi, Aikaterini organization: Aristotle University School of Medicine, Papageorgiou General Hospital – sequence: 5 givenname: Stavrianna surname: Diavati fullname: Diavati, Stavrianna organization: National & Kapodistrian University of Athens, Medical School – sequence: 6 givenname: Antonios orcidid: 0000-0003-0220-0762 surname: Tsimpidakis fullname: Tsimpidakis, Antonios organization: National & Kapodistrian University of Athens, Medical School – sequence: 7 givenname: Sabine surname: Kruger‐Krasagakis fullname: Kruger‐Krasagakis, Sabine organization: University General Hospital of Heraklion – sequence: 8 givenname: Aikaterini surname: Doxastaki fullname: Doxastaki, Aikaterini organization: University General Hospital of Heraklion – sequence: 9 givenname: Leonidas surname: Marinos fullname: Marinos, Leonidas organization: “Evangelismos” General Hospital – sequence: 10 givenname: Stella surname: Kaliampou fullname: Kaliampou, Stella organization: National & Kapodistrian University of Athens, Medical School – sequence: 11 givenname: Maria surname: Gerochristou fullname: Gerochristou, Maria organization: National & Kapodistrian University of Athens, Medical School – sequence: 12 givenname: Marios surname: Koumourtzis fullname: Koumourtzis, Marios organization: National & Kapodistrian University of Athens, Medical School – sequence: 13 givenname: Vasiliki orcidid: 0000-0003-0421-9424 surname: Pappa fullname: Pappa, Vasiliki organization: University General Hospital “Attikon” – sequence: 14 givenname: Efrosini surname: Kypraiou fullname: Kypraiou, Efrosini organization: National & Kapodistrian University of Athens, Medical School – sequence: 15 givenname: Vassilis surname: Kouloulias fullname: Kouloulias, Vassilis organization: National & Kapodistrian University of Athens, Medical School – sequence: 16 givenname: Konstantinos surname: Angelopoulos fullname: Angelopoulos, Konstantinos organization: National & Kapodistrian University of Athens, Medical School – sequence: 17 givenname: Alexandros orcidid: 0000-0003-1856-3381 surname: Machairas fullname: Machairas, Alexandros organization: National & Kapodistrian University of Athens, Medical School – sequence: 18 givenname: Theodoros surname: Vassilakopoulos fullname: Vassilakopoulos, Theodoros organization: National & Kapodistrian University of Athens, Medical School – sequence: 19 givenname: Vasiliki surname: Papadopoulou fullname: Papadopoulou, Vasiliki organization: Aristotle University School of Medicine, Papageorgiou General Hospital – sequence: 20 givenname: Athanasios surname: Tsamaldoupis fullname: Tsamaldoupis, Athanasios organization: Aristotle University School of Medicine, Papageorgiou General Hospital – sequence: 21 givenname: Elisavet orcidid: 0000-0001-8732-0610 surname: Georgiou fullname: Georgiou, Elisavet organization: Aristotle University School of Medicine, Papageorgiou General Hospital – sequence: 22 givenname: Triantafyllia surname: Koletsa fullname: Koletsa, Triantafyllia organization: Aristotle University School of Medicine – sequence: 23 givenname: Alexander surname: Stratigos fullname: Stratigos, Alexander organization: National & Kapodistrian University of Athens, Medical School – sequence: 24 givenname: Marina surname: Siakantaris fullname: Siakantaris, Marina organization: National & Kapodistrian University of Athens, Medical School – sequence: 25 givenname: Maria surname: Angelopoulou fullname: Angelopoulou, Maria organization: National & Kapodistrian University of Athens, Medical School |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39526550$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1ks1u1DAUhS1URKeFBS-ALLEBadL6-ieZsEEw_BVVYtO95bEd6pETB9tpNTv2bHhGngQPGSpAwhvbup-P7rk-J-hoCINF6DGQMyjr3G3NGTSi5vfQAlgtKl4zeoQWhABULRHtMTpJaVuujAJ_gI5ZK2gtBFmgb2vvBqeVx51VeYo2LXGO5djbIeMwZheGhNVgcJiyDr1N2A14jK5XcYf1lNVgw5Tw6x9fv2vrPfa7frwOvUovsMJFyJfCbYjeLHE_-ex00bVxWUo5hjRand2NxSlPZvcQ3e-UT_bRYT9FV-_eXq0_VJef3l-sX11WmhPOKyU2rWGK1BqIaQgz2gKImtoWDOWGbzjQTqx4C5x1dcd002waDloZxUUN7BS9nGXHadNbs28oKi8PnmRQTv5dGdy1_BxuJFBCVjVpi8Kzg0IMXyabsuxd2rufhyEZ0FUjiKC0oE__QbdhikOxV6gWBKFARaGe_NnSXS-__6kAz2dAl6GlaLs7BIjcZ0CWDMhfGSjs-czeOm93_wflxcc384uf8Hy2ug |
| Cites_doi | 10.1200/JCO.2006.09.6396 10.1016/j.jdin.2023.06.015 10.1001/jamadermatol.2013.7452 10.1684/ejd.2023.4617 10.1111/j.1365-2133.2012.11122.x 10.1200/JCO.2001.19.16.3602 10.1080/10428190802064925 10.1016/j.jaad.2013.04.047 10.1002/hon.2584 10.1016/j.ejca.2023.113014 10.1007/s12185-014-1728-2 10.1002/cam4.865 10.1182/blood-2004-09-3502 10.1182/blood-2008-10-184168 10.1016/j.ijrobp.2013.07.019 10.2340/00015555-1112 10.1038/modpathol.2008.159 10.1001/archderm.141.9.1139 10.1016/j.jaad.2020.07.028 10.1080/0284186X.2021.1956689 10.1016/j.jaad.2022.04.032 10.1080/10428194.2022.2098287 10.3390/cancers16051034 10.1200/JCO.2005.03.6285 10.1182/blood-2018-11-881268 |
| ContentType | Journal Article |
| Copyright | 2024 The Author(s). published by Wiley Periodicals LLC on behalf of the International Society of Dermatology. 2024 The Author(s). International Journal of Dermatology published by Wiley Periodicals LLC on behalf of the International Society of Dermatology. 2024. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2024 The Author(s). published by Wiley Periodicals LLC on behalf of the International Society of Dermatology. – notice: 2024 The Author(s). International Journal of Dermatology published by Wiley Periodicals LLC on behalf of the International Society of Dermatology. – notice: 2024. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7U7 C1K H94 K9. NAPCQ 7X8 5PM |
| DOI | 10.1111/ijd.17564 |
| DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Immunology Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Real‐world outcomes of PCBCLs |
| EISSN | 1365-4632 |
| EndPage | 889 |
| ExternalDocumentID | PMC12008609 39526550 10_1111_ijd_17564 IJD17564 |
| Genre | researchArticle Multicenter Study Journal Article |
| GeographicLocations | Greece |
| GeographicLocations_xml | – name: Greece |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 24P 29J 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AAQQT AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGQPQ AGYGG AHBTC AHEFC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 CYRXZ D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M J5H K48 KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WVDHM WXI WXSBR XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGXDD AIDQK AIDYY CITATION CGR CUY CVF ECM EIF NPM 7T5 7U7 C1K H94 K9. NAPCQ 7X8 5PM |
| ID | FETCH-LOGICAL-c4044-a5b9d3a06c10d703dce11562e91d24d4b412f5849143f6f3c77b741cada45613 |
| IEDL.DBID | DR2 |
| ISSN | 0011-9059 1365-4632 |
| IngestDate | Tue Sep 30 17:04:01 EDT 2025 Fri Jul 11 04:50:56 EDT 2025 Fri Jul 25 10:10:27 EDT 2025 Mon Jul 21 05:28:40 EDT 2025 Wed Oct 01 06:00:33 EDT 2025 Sat Apr 19 09:10:29 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | primary cutaneous follicle center lymphoma primary cutaneous diffuse large b‐cell lymphoma primary cutaneous marginal zone lymphoma primary cutaneous b‐cell lymphoma cutaneous lymphoma |
| Language | English |
| License | Attribution-NonCommercial 2024 The Author(s). International Journal of Dermatology published by Wiley Periodicals LLC on behalf of the International Society of Dermatology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4044-a5b9d3a06c10d703dce11562e91d24d4b412f5849143f6f3c77b741cada45613 |
| Notes | Conflict of interest: None. These authors have equally contributed to this manuscript. Funding source: None. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-0220-0762 0000-0001-8732-0610 0000-0001-9340-9152 0000-0003-0421-9424 0000-0003-1856-3381 0000-0002-1156-7139 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fijd.17564 |
| PMID | 39526550 |
| PQID | 3191502125 |
| PQPubID | 5776 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_12008609 proquest_miscellaneous_3128750522 proquest_journals_3191502125 pubmed_primary_39526550 crossref_primary_10_1111_ijd_17564 wiley_primary_10_1111_ijd_17564_IJD17564 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | May 2025 |
| PublicationDateYYYYMMDD | 2025-05-01 |
| PublicationDate_xml | – month: 05 year: 2025 text: May 2025 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Hoboken |
| PublicationTitle | International journal of dermatology |
| PublicationTitleAlternate | Int J Dermatol |
| PublicationYear | 2025 |
| Publisher | Blackwell Publishing Ltd John Wiley and Sons Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: John Wiley and Sons Inc |
| References | 2023; 13 2013; 69 2023; 33 2012; 167 2013; 87 2020; 83 2015; 101 2019; 37 2009; 113 2014; 150 2022; 63 2024; 16 2016; 5 2023; 190S1 2005; 141 2023; 88 2006; 24 2011; 91 2005; 105 2008; 49 2001; 19 2008; 21 2021; 60 2019; 133 2007; 25 e_1_2_8_24_1 e_1_2_8_25_1 e_1_2_8_26_1 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_21_1 e_1_2_8_22_1 e_1_2_8_23_1 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_14_1 e_1_2_8_15_1 e_1_2_8_16_1 e_1_2_8_10_1 e_1_2_8_11_1 e_1_2_8_12_1 |
| References_xml | – volume: 63 start-page: 2832 issue: 12 year: 2022 end-page: 2846 article-title: Clinical features and treatment outcomes for primary cutaneous CD4+ small/medium T‐cell lymphoproliferative disorder: a retrospective cohort study from the Dana‐Farber Cancer Institute and updated literature review publication-title: Leuk Lymphoma – volume: 37 start-page: 43 issue: Suppl 1 year: 2019 end-page: 47 article-title: Cutaneous lymphomas—an update 2019 publication-title: Hematol Oncol – volume: 13 start-page: 28 year: 2023 end-page: 29 article-title: Management strategies and survival in cutaneous B‐cell lymphoma: a population based study publication-title: JAAD Int – volume: 21 start-page: 1517 issue: 12 year: 2008 end-page: 1526 article-title: Primary cutaneous marginal zone B‐cell lymphoma: a molecular and clinicopathological study of cases from Asia, Germany, and the United States publication-title: Mod Pathol – volume: 91 start-page: 521 issue: 5 year: 2011 end-page: 525 article-title: Survival data for 299 patients with primary cutaneous lymphomas: a monocentre study publication-title: Acta Derm Venereol – volume: 60 start-page: 1361 issue: 10 year: 2021 end-page: 1368 article-title: Primary cutaneous indolent B‐cell lymphomas—a retrospective multicenter analysis and a review of literature publication-title: Acta Oncol – volume: 69 start-page: 357 issue: 3 year: 2013 end-page: 365 article-title: Primary cutaneous marginal zone B‐cell lymphoma: response to treatment and disease‐free survival in a series of 137 patients publication-title: J Am Acad Dermatol – volume: 190S1 year: 2023 article-title: Time to next treatment in primary cutaneous B cell lymphoma: experience on 98 patients publication-title: Eur J Cancer – volume: 87 start-page: 719 issue: 4 year: 2013 end-page: 725 article-title: Treatment and outcomes in patients with primary cutaneous B‐cell lymphoma: the BC Cancer Agency experience publication-title: Int J Radiat Oncol Biol Phys – volume: 5 start-page: 2740 issue: 10 year: 2016 end-page: 2755 article-title: Primary cutaneous B‐cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: comparison with current classification and definition of prognostic markers publication-title: Cancer Med – volume: 133 start-page: 1703 issue: 16 year: 2019 end-page: 1714 article-title: The 2018 update of the WHO‐EORTC classification for primary cutaneous lymphomas publication-title: Blood – volume: 33 start-page: 664 issue: 6 year: 2023 end-page: 673 article-title: Epidemiological trends in cutaneous lymphomas in Greece publication-title: Eur J Dermatol – volume: 16 start-page: 1034 issue: 5 year: 2024 article-title: A descriptive study of 103 primary cutaneous B‐cell lymphomas: clinical and pathological characteristics and treatment from the Spanish Lymphoma Oncology Group (GOTEL) publication-title: Cancers (Basel) – volume: 113 start-page: 5064 issue: 21 year: 2009 end-page: 5073 article-title: Cutaneous lymphoma incidence patterns in the United States: a population‐based study of 3884 cases publication-title: Blood – volume: 19 start-page: 3602 issue: 16 year: 2001 end-page: 3610 article-title: Prognostic factors in primary cutaneous large B‐cell lymphomas: a European multicenter study publication-title: J Clin Oncol – volume: 49 start-page: 1094 issue: 6 year: 2008 end-page: 1103 article-title: Primary cutaneous B‐cell lymphomas—clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO‐EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome publication-title: Leuk Lymphoma – volume: 101 start-page: 273 issue: 3 year: 2015 end-page: 278 article-title: Clinical features and treatment outcomes of primary cutaneous B‐cell lymphoma: a single‐center analysis in South Korea publication-title: Int J Hematol – volume: 141 start-page: 1139 issue: 9 year: 2005 end-page: 1145 article-title: Primary cutaneous marginal zone B‐cell lymphoma: clinical and therapeutic features in 50 cases publication-title: Arch Dermatol – volume: 24 start-page: 1376 issue: 9 year: 2006 end-page: 1382 article-title: Prognostic factors in primary cutaneous B‐cell lymphoma: the Italian Study Group for Cutaneous Lymphomas publication-title: J Clin Oncol – volume: 167 start-page: 1118 issue: 5 year: 2012 end-page: 1123 article-title: Primary cutaneous B‐cell lymphoma in Nottinghamshire U.K.: prognosis of subtypes defined in the WHO‐EORTC classification publication-title: Br J Dermatol – volume: 105 start-page: 3768 issue: 10 year: 2005 end-page: 3785 article-title: WHO‐EORTC classification for cutaneous lymphomas publication-title: Blood – volume: 25 start-page: 1581 issue: 12 year: 2007 end-page: 1587 article-title: Reclassification of 300 primary cutaneous B‐Cell lymphomas according to the new WHO‐EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers publication-title: J Clin Oncol – volume: 150 start-page: 535 issue: 5 year: 2014 end-page: 541 article-title: Improvement of survival in patients with primary cutaneous diffuse large B‐cell lymphoma, leg type in France publication-title: JAMA Dermatol – volume: 88 start-page: 203 issue: 1 year: 2023 end-page: 205 article-title: Treatment at high‐volume facilities is associated with improved overall survival for patients with cutaneous B‐cell lymphoma publication-title: J Am Acad Dermatol – volume: 83 start-page: 1535 issue: 5 year: 2020 end-page: 1538 article-title: Systemic rituximab for the treatment of the indolent forms of primary cutaneous B‐cell lymphomas: data from the Spanish Primary Cutaneous Lymphoma Registry publication-title: J Am Acad Dermatol – ident: e_1_2_8_7_1 doi: 10.1200/JCO.2006.09.6396 – ident: e_1_2_8_11_1 doi: 10.1016/j.jdin.2023.06.015 – ident: e_1_2_8_10_1 doi: 10.1001/jamadermatol.2013.7452 – ident: e_1_2_8_12_1 doi: 10.1684/ejd.2023.4617 – ident: e_1_2_8_13_1 doi: 10.1111/j.1365-2133.2012.11122.x – ident: e_1_2_8_8_1 doi: 10.1200/JCO.2001.19.16.3602 – ident: e_1_2_8_17_1 doi: 10.1080/10428190802064925 – ident: e_1_2_8_20_1 doi: 10.1016/j.jaad.2013.04.047 – ident: e_1_2_8_4_1 doi: 10.1002/hon.2584 – ident: e_1_2_8_22_1 doi: 10.1016/j.ejca.2023.113014 – ident: e_1_2_8_16_1 doi: 10.1007/s12185-014-1728-2 – ident: e_1_2_8_9_1 doi: 10.1002/cam4.865 – ident: e_1_2_8_2_1 doi: 10.1182/blood-2004-09-3502 – ident: e_1_2_8_5_1 doi: 10.1182/blood-2008-10-184168 – ident: e_1_2_8_15_1 doi: 10.1016/j.ijrobp.2013.07.019 – ident: e_1_2_8_25_1 doi: 10.2340/00015555-1112 – ident: e_1_2_8_19_1 doi: 10.1038/modpathol.2008.159 – ident: e_1_2_8_21_1 doi: 10.1001/archderm.141.9.1139 – ident: e_1_2_8_23_1 doi: 10.1016/j.jaad.2020.07.028 – ident: e_1_2_8_18_1 doi: 10.1080/0284186X.2021.1956689 – ident: e_1_2_8_26_1 doi: 10.1016/j.jaad.2022.04.032 – ident: e_1_2_8_24_1 doi: 10.1080/10428194.2022.2098287 – ident: e_1_2_8_14_1 doi: 10.3390/cancers16051034 – ident: e_1_2_8_6_1 doi: 10.1200/JCO.2005.03.6285 – ident: e_1_2_8_3_1 doi: 10.1182/blood-2018-11-881268 |
| SSID | ssj0013214 |
| Score | 2.4376998 |
| Snippet | Background
Primary cutaneous B‐cell lymphomas (PCBCLs) are rare cutaneous neoplasms with limited literature regarding treatment options and associated... Primary cutaneous B-cell lymphomas (PCBCLs) are rare cutaneous neoplasms with limited literature regarding treatment options and associated treatment outcomes.... BackgroundPrimary cutaneous B‐cell lymphomas (PCBCLs) are rare cutaneous neoplasms with limited literature regarding treatment options and associated treatment... Clinical features, treatment options and outcomes in PCBCL. |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 882 |
| SubjectTerms | Aged Clinical outcomes cutaneous lymphoma Female Follow-Up Studies Greece Humans Lymphoma Lymphoma, B-Cell - mortality Lymphoma, B-Cell - pathology Lymphoma, B-Cell - therapy Lymphoma, B-Cell, Marginal Zone - mortality Lymphoma, B-Cell, Marginal Zone - pathology Lymphoma, B-Cell, Marginal Zone - therapy Lymphoma, Follicular - mortality Lymphoma, Follicular - pathology Lymphoma, Follicular - therapy Lymphoma, Large B-Cell, Diffuse - mortality Lymphoma, Large B-Cell, Diffuse - pathology Lymphoma, Large B-Cell, Diffuse - therapy Male Middle Aged Neoplasms Original Patients primary cutaneous b‐cell lymphoma primary cutaneous diffuse large b‐cell lymphoma primary cutaneous follicle center lymphoma primary cutaneous marginal zone lymphoma Radiation therapy Retrospective Studies Skin Neoplasms - diagnosis Skin Neoplasms - mortality Skin Neoplasms - pathology Skin Neoplasms - therapy Steroid hormones Treatment Outcome |
| Title | Clinical features, treatment options and outcomes in primary cutaneous B‐cell lymphomas: a real‐world, multicenter, retrospective study |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fijd.17564 https://www.ncbi.nlm.nih.gov/pubmed/39526550 https://www.proquest.com/docview/3191502125 https://www.proquest.com/docview/3128750522 https://pubmed.ncbi.nlm.nih.gov/PMC12008609 |
| Volume | 64 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 0011-9059 databaseCode: DR2 dateStart: 19970101 customDbUrl: isFulltext: true eissn: 1365-4632 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0013214 providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VHhAX3o9AqQziwGGzSvxqQk-8qlKpCKEi9YAU2bEttl0laJMc4MSdC7-RX9Kx89AuFRLiFsnOazLj-Zz5_BngGcWUm2fGxKWv_3MnWKxlxmKnROZUlrhM-rXDx-_l4Sd-dCpOt2B_XAvT60NMP9x8ZITx2ge40s1akC_OzBxzn_RaoCkToUT7ka5VEHpdb_8LMEcMMagKeRbPdOZmLroEMC_zJNfxa0hABzfg8_joPe_kfN61el5-_0PV8T_f7SZcH4Apedl70i3YstVtuHo8lN7vwM9BQXRJnA1ioM2MTCx1UvfcGKIqQ-quxfvZhiwq8rUXsyBlhyDU1l1DXv3-8ctXC8jyGzqSZye9IIrghZbYEPRbZySwHL057GqGTe2qHheEkiCHexdODt6evD6Mh50c4pInnMdK6NwwlcgyTQyOMWhRRKKS2jw1lBuueUodQqEc0ZuTjpV7exqhTqmM8gCP3YPtqq7sAyCJZakV0suGJVwzp03OhVEZxf7WChHB0_GTFsMrFuM8B61aBKtGsDN-7GII2abAsQjBMWZyvMaTqRmDzdukNxH2wQmm3_qPRnC_943pLiz3Ow2IJIJsw2umDl7Ie7OlWnwJgt6pJ6HIJI_gefCKvz958e7oTTh4-O9dH8E16jctDizNHdhuV519jEiq1btwhfIPuyFwLgAmPx9B |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB6VIgEXxJvQAgZx4LCpHMd2E8SFV7Ut3YrDIvUWObEtFq0StI9Db71z4Tf2lzDjPLSrColbJE-c2OPxfLbH3wC8Eehy88zauKLzf-lVGpc6S2NvVOZNxn2m6e7w5EyPv8uTc3W-A-_7uzAtP8Sw4UaWEeZrMnDakN6w8tlPe4DOT8sbcFNqwWlMC_lt4wyhZfamTcAcUUTHK0RxPMOr297oGsS8Him5iWCDCzq6B3c77Mg-tMq-DzuufgC3Jt3p-EP43ZF8zpl3ga9zOWJDIDlr2vAVZmrLmvUKm-uWbFazXy3fBKvWiBNds16yj1eXf2hDn80vUNcUQPSOGYYVzbEgUKyOWAhEpP91ixEWrRZNf2eTBcbaRzA9-jL9NI67ZAtxJbmUsVFlblPDdZVwi9MANhnBohYuT6yQVpYyER7RSo4Ay2ufVoeHJaKRylhDGCx9DLt1U7unwLhLE6c0MXtxWaa-tLlU1mQC5Z1TKoLXfZ8XXROLfimCiimCYiLY77VRdFa1LHC6QPyKzhbreDUUoz1Qn7RdhDK4BqTsfCKCJ63yhq-kOSUDUDyCbEutgwBxbW-X1LMfgXM7oTgRzfMI3oYR8O8_L45PPoeHZ_8v-hJuj6eT0-L0-OzrHtwRlGM4BFXuw-5qsXbPEfisyhdhfP8FOg0B0w |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIlVcypsGChjEgcNmlYftJnACyqottEKoSD0gRU5si21XSbWbHODEvZf-Rn4JM85Du1RIiFskO7EzmfF8jj9_BngRYcpNE639gtb_uRWxn8sk9q0SiVVJYBNJe4cPj-TeF35wIk7W4HW_F6bVhxh-uFFkuPGaAvxc26Ugn57qMeY-ya_BdS5xdkWI6HO0tITQCnvTP8AUQUQnK0Q0nuHW1WR0BWFeJUouA1iXgSY34Wvf95Z4cjZu6nxc_PhD1vE_X-4WbHbIlL1pXek2rJnyDmwcdmvvd-GikxCdMWucGuhixAaaOqtacgxTpWZVU2N7ZsGmJTtv1SxY0SAKNVWzYG9__byk5QI2-46eRPSkV0wxfNAMC5yA64g5miOZw8xHWFTPq35HKHN6uPfgePL--N2e3x3l4Bc84NxXIk91rAJZhIHGQQYtilBURiYNdcQ1z3kYWcRCKcI3K21c7OzkiHUKpRUhvPg-rJdVabaABSYOjZCkGxbwPLa5TrnQKomwvjFCePC8_6RZ94pZP9FBq2bOqh5s9x8762J2keFghOgYUzk-49lQjNFGNmlNhHVwhkln_0UePGh9Y2glTumoARF4kKx4zVCBlLxXS8rpN6foHRILRQapBy-dV_y959n-wa67ePjvVZ_CxqfdSfZx_-jDI7gR0QHGjrG5Dev1vDGPEVXV-RMXPb8BvAohNQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+features%2C+treatment+options+and+outcomes+in+primary+cutaneous+B%E2%80%90cell+lymphomas%3A+a+real%E2%80%90world%2C+multicenter%2C+retrospective+study&rft.jtitle=International+journal+of+dermatology&rft.au=Nikolaou%2C+Vasiliki&rft.au=Ioannis%E2%80%90Alexios+Koumprentziotis&rft.au=Papadavid%2C+Evangelia&rft.au=Patsatsi%2C+Aikaterini&rft.date=2025-05-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=0011-9059&rft.eissn=1365-4632&rft.volume=64&rft.issue=5&rft.spage=882&rft.epage=889&rft_id=info:doi/10.1111%2Fijd.17564&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0011-9059&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0011-9059&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0011-9059&client=summon |